ASCO 2026: Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5 Year Follow-up and Response Analyses from the Phase 3 EV-302 Study - UroToday

ASCO 2026: Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5 Year Follow-up and Response Analyses from the Phase 3 EV-302 Study    UroToday Updated EV-302 Trial Results Show Improved Survival With EV+P in Metastatic Urothelial Cancer    Oncology News Central Enfortumab Vedotin/Pembrolizumab Maintains OS Benefit in Urothelial Carcinoma    CancerNetwork CDSCO approves Astellas’ PADCEV for First-Line Advanced Bladder Cancer Treatment    ThePrint EV-302 at ASCO 2026: 3.5-Year Follow-Up Confirms Long-Term Benefit of EV Plus Pembro in la/mUC    Oncodaily

Original source: Google News